These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 7448717)

  • 1. Relationship between primary breast tumor receptor status and patient survival.
    Blamey RW; Bishop HM; Blake JR; Doyle PJ; Elston CW; Haybittle JL; Nicholson RI; Griffiths K
    Cancer; 1980 Dec; 46(12 Suppl):2765-9. PubMed ID: 7448717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognosis and treatment of patients with breast tumors of one centimeter or less and negative axillary lymph nodes.
    Fisher B; Dignam J; Tan-Chiu E; Anderson S; Fisher ER; Wittliff JL; Wolmark N
    J Natl Cancer Inst; 2001 Jan; 93(2):112-20. PubMed ID: 11208880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estrogen receptors and breast cancer.
    Nicholson RI; Griffiths K; Blamey RW; Bishop HM; Haybittle JL
    Environ Health Perspect; 1981 Apr; 38():143-6. PubMed ID: 7238443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Steroid hormone receptors and clinical usefulness in human breast cancer.
    Nomura Y; Yamagata J; Takenaka K; Tashiro H
    Cancer; 1980 Dec; 46(12 Suppl):2880-3. PubMed ID: 7448732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Findings from recent National Surgical Adjuvant Breast and Bowel Project adjuvant studies in stage I breast cancer.
    Fisher B; Jeong JH; Dignam J; Anderson S; Mamounas E; Wickerham DL; Wolmark N
    J Natl Cancer Inst Monogr; 2001; (30):62-6. PubMed ID: 11773294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant chemotherapy, antiestrogen therapy and immunotherapy for stage II breast cancer: 45-month follow-up of a prospective, randomized clinical trial.
    Hubay CA; Pearson OH; Marshall JS; Rhodes RS; DeBanne SM; Rosenblatt J; Mansour EG; Hermann RE; Jones JC; Flynn WJ; Eckert C; McGuire WL
    Cancer; 1980 Dec; 46(12 Suppl):2805-8. PubMed ID: 7004624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The prognostic effect of estrogen receptor status differs for younger versus older breast cancer patients.
    Sopik V; Sun P; Narod SA
    Breast Cancer Res Treat; 2017 Sep; 165(2):391-402. PubMed ID: 28601929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estrogen receptors and response to endocrine therapy and cytotoxic chemotherapy in advanced breast cancer.
    Rubens RD; Hayward JL
    Cancer; 1980 Dec; 46(12 Suppl):2922-4. PubMed ID: 7448737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Changing receptor status and treatment in breast cancer].
    Nomura Y
    Gan No Rinsho; 1983 May; 29(6):644-7. PubMed ID: 6876434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The variation and clinical significance of hormone receptors and Her-2 status from primary to metastatic lesions in breast cancer patients.
    Zhu YY; Si W; Ji TF; Guo XQ; Hu Y; Yang JL
    Tumour Biol; 2016 Jun; 37(6):7675-84. PubMed ID: 26687919
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abundant tumor infiltrating lymphocytes after primary systemic chemotherapy predicts poor prognosis in estrogen receptor-positive/HER2-negative breast cancers.
    Watanabe T; Hida AI; Inoue N; Imamura M; Fujimoto Y; Akazawa K; Hirota S; Miyoshi Y
    Breast Cancer Res Treat; 2018 Feb; 168(1):135-145. PubMed ID: 29168063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy.
    Kuukasjärvi T; Kononen J; Helin H; Holli K; Isola J
    J Clin Oncol; 1996 Sep; 14(9):2584-9. PubMed ID: 8823339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proportion of estrogen or progesterone receptor expressing cells in breast cancers and response to endocrine therapy.
    Honma N; Horii R; Iwase T; Saji S; Younes M; Ito Y; Akiyama F
    Breast; 2014 Dec; 23(6):754-62. PubMed ID: 25176593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic effect of estrogen receptor status across age in primary breast cancer.
    Bentzon N; Düring M; Rasmussen BB; Mouridsen H; Kroman N
    Int J Cancer; 2008 Mar; 122(5):1089-94. PubMed ID: 17960621
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Significance of GATA-3 expression in outcomes of patients with breast cancer who received systemic chemotherapy and/or hormonal therapy and clinicopathologic features of GATA-3-positive tumors.
    Gulbahce HE; Sweeney C; Surowiecka M; Knapp D; Varghese L; Blair CK
    Hum Pathol; 2013 Nov; 44(11):2427-31. PubMed ID: 23998430
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Additional value of the 70-gene signature and levels of ER and PR for the prediction of outcome in tamoxifen-treated ER-positive breast cancer.
    Kok M; Koornstra RH; Mook S; Hauptmann M; Fles R; Jansen MP; Berns EM; Linn SC; Van 't Veer LJ
    Breast; 2012 Dec; 21(6):769-78. PubMed ID: 22738860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overexpression of cyclin D1 messenger RNA predicts for poor prognosis in estrogen receptor-positive breast cancer.
    Kenny FS; Hui R; Musgrove EA; Gee JM; Blamey RW; Nicholson RI; Sutherland RL; Robertson JF
    Clin Cancer Res; 1999 Aug; 5(8):2069-76. PubMed ID: 10473088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between steroid receptors and response to endocrine therapy and cytotoxic chemotherapy in metastatic breast cancer.
    Young PC; Ehrlich CE; Einhorn LH
    Cancer; 1980 Dec; 46(12 Suppl):2961-3. PubMed ID: 7448744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Prognostic value of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in node positive breast cancer patients treated by mastectomy].
    Wang SL; Li YX; Song YW; Wang WH; Jin J; Liu YP; Liu XF; Yu ZH
    Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):520-5. PubMed ID: 21029696
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer.
    Foekens JA; Look MP; Peters HA; van Putten WL; Portengen H; Klijn JG
    J Natl Cancer Inst; 1995 May; 87(10):751-6. PubMed ID: 7563153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.